The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C09 | Agents acting on the renin-angiotensin system | |
| 3 | C09D | Angiotensin II antagonists, combinations | |
| 4 | C09DB | Angiotensin II antagonists and calcium channel blockers |
| Code | Title | |
|---|---|---|
| C09DB01 | Valsartan and amlodipine | |
| C09DB02 | Olmesartan medoxomil and amlodipine | |
| C09DB04 | Telmisartan and amlodipine | |
| C09DB05 | Irbesartan and amlodipine | |
| C09DB06 | Losartan and amlodipine | |
| C09DB07 | ||
| C09DB09 |
| Active Ingredient | Description | |
|---|---|---|
| Candesartan and Amlodipine |
Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, candesartan and a dihydropyridinic calcium channel blocker, amlodipine. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
|
| Irbesartan and Amlodipine |
The pharmacodynamic properties of each drug, irbesartan and amlodipine, provide an additive antihypertensive effect when administered in combination compared to the effect of each drug administered separately. Irbesartan is a specific angiotensin II receptor antagonist (AT1 subtype) and amlodipine is a dihydropyridine calcium antagonist. Both AT1 receptor antagonists and calcium channel blockers lower blood pressure by reducing peripheral resistance, but calcium influx blockade and reduction of angiotensin II vasoconstriction are complementary mechanisms. |
|
| Olmesartan medoxomil and Amlodipine |
Combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a calcium channel blocker, amlodipine besilate. The combination of these active ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
|
| Telmisartan and Amlodipine |
Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, telmisartan, and a dihydropyridinic calcium channel blocker, amlodipine. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
|
| Valsartan and Amlodipine |
Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| APROVASC Film-coated tablet | Marketing Authorisation Holder | MPI, Generic | |
| CLODIPAN Hard capsule | Medicines Authority (MT) | MPI, EU: SmPC | |
| COPALIA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EXFORGE Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SEVIKAR Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TWYNSTA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
